The global biopharmaceutical industry is the most rapidly growing industry in the science and technology sector owing to increasing R&D investments in biopharmaceutical drug development facilities. The global automation market in biopharmaceutical industry includes deployment of automation in biopharmaceutical academic research centers, manufacturing and research companies, clinical labs, and government approved labs.
One trend in the market is continuous manufacturing. Advantages of continuous operations are well-recognized in various industries. It completes the process in a shorter time as it omits the hold steps, reduces shut down time, and reduces the labor requirement. Over the decades, upstream processing utilized this technology.”
According to the report, one driver in the market is use of automation in data acquisition. Traditionally, research labs collect data manually and store it in spreadsheets. This method is not only time-consuming but also affects operational efficiency and is prone to errors. It also restricts monitoring of data in real time. The biopharmaceutical industry is working on data collection and adding the information from spreadsheets to a database. Database collection of upstream and downstream processes is being utilized to create a library that increases operational efficiency and process optimization.
Further, the report states that one challenge in the market is high R&D cost. The biopharmaceutical industry is a rapidly growing industry in pharmaceuticals. Complex drugs are manufactured with the help of 3-D modeling and are produced with high efficacy and precision. These drugs can provide medication to medical issues that were once incurable. Currently, the biopharmaceutical industry is looking to yield new products to address diseases such as cancer, Alzheimer's disease, and hepatitis C. Innovations in the biopharmaceutical industry are highly expensive. The average cost associated with a new drug is around $2 billion, including the cost of unsuccessful drug approvals, out of which almost $400 million is the cost included in pre-clinical and clinical testing.
The global Automation in Biopharmaceutical market was valued at 1040 million US$ in 2018 and will reach 1590 million US$ by the end of 2025, growing at a CAGR of 6.2% during 2019-2025.
This report focuses on Automation in Biopharmaceutical volume and value at global level, regional level and company level. From a global perspective, this report represents overall Automation in Biopharmaceutical market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Automation in Biopharmaceutical in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Automation in Biopharmaceutical manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Danaher
GE
PerkinElmer
Tecan Trading
Thermo Fisher Scientific
Bruker
Peak Analysis & Automation
Waters
Capsugel
RheoSense
Eirechrom
BioProcess International
Novasep
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Clinical stage automation
Drug discovery stage automation
Segment by Application
Research and Development
Clinical
Summary:
Get latest Market Research Reports on Automation in Biopharmaceutical . Industry analysis & Market Report on Automation in Biopharmaceutical is a syndicated market report, published as Global Automation in Biopharmaceutical Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Automation in Biopharmaceutical market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.